Circulating microRNAs and Response to Neoadjuvant Chemotherapy in Breast Cancer

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorAtlas University

About this trial

This prospective observational study aims to investigate subtype-specific circulating microRNAs (miRNAs) and their association with response to neoadjuvant chemotherapy (NAC) in patients with breast cancer. Serum samples will be collected before NAC and prior to surgery, and changes in miRNA expression levels will be evaluated. Pathological complete response (pCR) and Miller-Payne scoring will be used to assess treatment response after NAC. The study also explores whether changes in circulating miRNA profiles can predict treatment response across different breast cancer subtypes. The findings may help identify biomarkers that support treatment planning and personalized therapy strategies.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Histologically confirmed breast cancer

Planned to receive neoadjuvant chemotherapy

Biologically female

Age ≥ 18 years

Disqualifiers

Presence of metastatic disease at diagnosis

Prior systemic chemotherapy for breast cancer

Pregnancy or breastfeeding

Active infection or uncontrolled comorbid conditions interfering with study participation

Trial population

Female patients diagnosed with breast cancer who are scheduled to undergo standard neoadjuvant chemotherapy at a single tertiary care center.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

80 Participants
are grouped into 1 trial group
Group A: Breast Cancer Cohort

Trial outcomes

Primary outcomes

1

Change in circulating microRNA expression levels before and after neoadjuvant chemotherapy

Quantitative assessment of selected serum microRNAs (miR-200a/b/c, miR-34a, miR-221/222, miR-155, miR-146a) using RT-PCR. Changes in expression levels will be compared between baseline and pre-surgery samples.

Time frame
Baseline (before NAC) and pre-surgery (after completion of NAC)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.